Health Care & Life Sciences » Biotechnology | Editas Medicine Inc.

Editas Medicine Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2015
2016
2017
2018
Cash & Short Term Investments
143,500.00
185,323.00
329,139.00
368,955
Total Accounts Receivable
1,019.00
88.00
679.00
30
Other Current Assets
466.00
1,772.00
2,381.00
5,791
Total Current Assets
144,985.00
187,183.00
332,199.00
374,776
Net Property, Plant & Equipment
2,130.00
40,378.00
39,442.00
40,232
Total Investments and Advances
-
1,621.00
1,619.00
5,378
Other Assets
2,248.00
-
-
-
Total Assets
149,363.00
229,182.00
373,260.00
420,386
ST Debt & Current Portion LT Debt
-
10,000.00
7,500.00
Accounts Payable
1,381.00
4,640.00
4,020.00
Other Current Liabilities
5,544.00
18,443.00
25,187.00
Total Current Liabilities
6,925.00
33,083.00
36,707.00
Long-Term Debt
-
35,096.00
33,431.00
Other Liabilities
25,637.00
26,396.00
95,042.00
Total Liabilities
32,562.00
94,575.00
165,180.00
Common Equity (Total)
83,114.00
134,607.00
208,080.00
Total Shareholders' Equity
116,801.00
134,607.00
208,080.00
Total Equity
116,801.00
134,607.00
208,080.00
Liabilities & Shareholders' Equity
149,363.00
229,182.00
373,260.00
Preferred Stock (Carrying Value)
199,915.00
-
-

About Editas Medicine

View Profile
Address
11 Hurley Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.editasmedicine.com
Updated 07/08/2019
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A.